Up to one-half of all lung transplant recipients eventually develop irreversible and disabling graft dysfunction due to obliterative bronchiolitis. This disease is thought to represent chronic airway rejection, although its pathogenesis is poorly understood. Effective treatment is painfully lacking. This article discusses the current concept of obliterative bronchiolitis with respect to its pathology, pathogenesis, and current and future treatment strategies.